Literature DB >> 12917249

Effect of amphotericin B treatment on kinetics of cytokines and parameters of fungal load in neutropenic rats with invasive pulmonary aspergillosis.

Martin J Becker1, Siem de Marie, Marcel H A M Fens, Henri A Verbrugh, Irma A J M Bakker-Woudenberg.   

Abstract

OBJECTIVE: The kinetics of various parameters of fungal load and cytokines were investigated, in order to acquire insight into the pathogenesis of invasive pulmonary aspergillosis (IPA) during antifungal treatment with amphotericin B.
METHODS: Neutropenic rats with left-sided IPA received either treatment with amphotericin B or remained untreated. At 0, 4, 8, 16, 24, 48, 72 and 120 h after fungal inoculation, the rats were dissected. The size of the macroscopic pulmonary lesions, the number of cfu and amounts of chitin were determined in the infected left lung. Galactomannan concentrations were measured both in the left lung and serum. The cytokines tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, interferon (IFN)-gamma, IL-4, IL-10, and the chemokines macrophage inflammatory protein (MIP)-2 and monocyte chemoattractant protein (MCP)-1 were determined quantitatively by ELISA in the infected left lung, uninfected right lung and serum.
RESULTS: Amphotericin B treatment of IPA resulted in changed aspect of pulmonary lesions and significantly reduced levels of left lung chitin (72 and 120 h), left lung galactomannan (72 and 120 h) and serum galactomannan (120 h), but not left lung cfu, compared with untreated infected rats. In addition, amphotericin B treatment resulted in a significant decrease in levels of left lung IL-6 (at 72 and 120 h), MIP-2 (at 120 h) and MCP-1 (at 120 h). No local or systemic increases in TNF-alpha, IL-1beta or IFN-gamma were observed during infection.
CONCLUSION: It is concluded that treatment with amphotericin B results in decreased fungal load in the infected lung. This reduction in fungal load probably results in a decreased local inflammatory response, as measured by decreased levels of IL-6, MIP-2 and MCP-1 in the infected lung.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12917249     DOI: 10.1093/jac/dkg367

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  20 in total

1.  Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis.

Authors:  Viviane Balloy; Michel Huerre; Jean-Paul Latgé; Michel Chignard
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

2.  Dramatic remission of nephrotic syndrome after unusual complication of mucormycosis in idiopathic membranous nephropathy.

Authors:  Wenling Ye; Yingyi Wang; Yubing Wen; Hang Li; Xuemei Li
Journal:  Int Urol Nephrol       Date:  2014-01-11       Impact factor: 2.370

3.  Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis.

Authors:  Sophia Koo; Julie M Bryar; Lindsey R Baden; Francisco M Marty
Journal:  J Clin Microbiol       Date:  2010-02-10       Impact factor: 5.948

4.  Antifungal and antihepatotoxic effects of sepia ink extract against oxidative stress as a risk factor of invasive pulmonary aspergillosis in neutropenic mice.

Authors:  Sohair R Fahmy; Amel M Soliman; Enas M Ali
Journal:  Afr J Tradit Complement Altern Med       Date:  2014-04-03

5.  Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis.

Authors:  S Kaur; V K Gupta; S Thiel; P U Sarma; T Madan
Journal:  Clin Exp Immunol       Date:  2007-03-05       Impact factor: 4.330

6.  Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: an emerging fungal disease.

Authors:  Florence Ader
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

7.  Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.

Authors:  Wendy W J van de Sande; Ron A A Mathot; Marian T ten Kate; Wim van Vianen; Mehri Tavakol; Bart J A Rijnders; Irma A J M Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2009-02-23       Impact factor: 5.191

8.  NAC is associated with additional alleviation of lung injury induced by invasive pulmonary aspergillosis in a neutropenic model.

Authors:  Peng Xu; Jie-Ming Qu; Jin-Fu Xu; Jing Zhang; Hong-Ni Jiang; Hui-Jun Zhang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

9.  Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis.

Authors:  Wendy W J van de Sande; Wim van Vianen; Marian T ten Kate; Jolanda Vissers; John Laurijsens; Mehri Tavakol; Bart J A Rijnders; Ron A A Mathot; Irma A J M Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2008-01-14       Impact factor: 5.191

Review 10.  Management of invasive aspergillosis in patients with COPD: rational use of voriconazole.

Authors:  Florence Ader; Anne-Lise Bienvenu; Blandine Rammaert; Saad Nseir
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.